Salix Pharmaceuticals Inc (SLXP)
Quote as of 12:34 PM ET 03/11/2010 (NASDAQ GS)
| Last: 30.61 |
Change: ($0.88) |
Percent Change: -2.79 |
Volume: 562,971 |
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. As of December 31, 2008, the Company?s products were XIFAXAN (rifaximin) Tablets 200 milligram; MOVIPREP; OSMOPREP, VISICOL Tablets, AZASAN Azathioprine Tablets, USP, 75/100 milligram; ANUSOL-HC 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC 25 milligram Suppository (Hydrocortisone Acetate); PROCTOCORT Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 milligram; PEPCID (famotidine) for Oral Suspension; Oral Suspension DIURIL (Chlorothiazide); APRISO (mesalamine) extended-release capsules 0.375 grams, and COLAZAL (balsalazide disodium) Capsules 750 milligram.
Latest News
10:49:57 AM 3/10/2010
Salix expects big drop in sales
Mar 10, 2010 (The News and Observer - McClatchy-Tribune Information Services via COMTEX) --
Salix Pharmaceuticals' fourth-quarter revenue and net income slightly exceeded analysts' expectations, but the Raleigh company projected first-quarter numbers that were surprisingly low.
8:27:11 PM 2/24/2010
FDA panel boosts Salix
Feb 24, 2010 (The News & Observer - McClatchy-Tribune Information Services via COMTEX) --
Salix Pharmaceuticals shares jumped as much as 18 percent in after-hours trading Tuesday after the company's application to market its best-selling drug Xifaxan for a serious liver disease got a thumbs up from a Food and Drug Administration advisory panel.
7:53:00 PM 2/23/2010
Stocks in focus for Wednesday
Salesforce.com, Limited Brands and Saks Inc. are among the companies whose shares are expected to be active during Wednesday's trading session.
5:59:00 PM 2/23/2010
Salix, Autodesk climb; STEC slides
Salix Pharmaceuticals Inc. shares surge as much as 18% in late trading after a Food and Drug Administration panel gave its approval to a new drug used to fight brain damage.